EXAS vs DGX

For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.

7% revenue growth year-over-year, versus 11. 8% for Quest Diagnostics Incorporated (DGX). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Exact Sciences Corporation (EXAS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Quest Diagnostics Incorporated is actually cheaper at 17.

8x.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to +0. 4% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: EXAS returned +1669% versus DGX's +181. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus Exact Sciences Corporation's 0. 12β — meaning EXAS is approximately 64% more volatile than DGX relative to the S&P 500. On balance sheet safety, Quest Diagnostics Incorporated (DGX) carries a lower debt/equity ratio of 95% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.

7% versus 11. 8% for Quest Diagnostics Incorporated (DGX). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to 13. 8% for Quest Diagnostics Incorporated. Over a 3-year CAGR, EXAS leads at 15. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Quest Diagnostics Incorporated (DGX) is the more profitable company, earning 9.

0% net margin versus -6. 4% for Exact Sciences Corporation — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus -6. 4% for EXAS. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Quest Diagnostics Incorporated (DGX) trades at 17.

8x forward P/E versus 582. 8x for Exact Sciences Corporation — 565. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DGX: 15. 6% to $220. 57.

In this comparison, DGX (1.

6% yield) pays a dividend. EXAS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, DGX: +181. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EXAS is a mid-cap high-growth stock; DGX is a mid-cap quality compounder stock. DGX pays a dividend while EXAS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.